Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;12(3):326-32.
doi: 10.1111/j.1440-1843.2007.01083.x.

Lung cancer: new surgical approaches

Affiliations
Review

Lung cancer: new surgical approaches

J Timothy Sherwood et al. Respirology. 2007 May.

Abstract

Over the past two decades, many surgical specialties have seen a dramatic shift from large, open operations with wide incisions towards more-minimal incisions and less-invasive procedures. Surgical techniques for lung cancer are no exception, and today, video-assisted thoracic surgical lobectomies are being performed with increasing frequency in large-volume thoracic practices. Despite these new surgical techniques, however, the most substantial innovations that have changed surgical outcomes occurred away from the operative theatre. In lung cancer, in particular, the last 20 years have witnessed the clinical debut of more sophisticated, more elegant and more accurate imaging modalities for improved screening, diagnostic and staging, such as the spiral CT scan, PET scan, PET/CT and the endobronchial ultrasound machine. This technology has been complimented by more targeted chemotherapeutic regimens, novel methods of administering more accurate and more concentrated doses of radiation therapy, and innovative local excisional methods, such as the Cyberknife and radiofrequency ablation. The result has been that surgical excision, although remaining the most effective local therapeutic modality in early-stage lung cancer, is no longer the 'lone ranger' treatment, but rather is part of a complex mosaic of multimodality therapy. As scientific advances continue to be translated into the clinic, this trend will inexorably continue with the advent of a molecular staging system using molecular markers and tumour profiling, which ultimately could enhance our ability to predict tumour chemosensitivity. In this brave new world, however, complete surgical resection of the lung cancer will continue to be critical.

PubMed Disclaimer